Ibere Pharmaceuticals

Company Profile

Ibere Pharmaceuticals had its IPO on 2021-04-20 under the ticker symbol IBER.

The company operates in the Financial Services sector and Shell Companies industry. Ibere Pharmaceuticals has a staff strength of 0 employees.

Stock update

Shares of Ibere Pharmaceuticals opened at $10.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $10.18 - $10.18, and closed at $10.18.

This is a -0.29% slip from the previous day's closing price.

A total volume of 44,499 shares were traded at the close of the day’s session.

In the last one week, shares of Ibere Pharmaceuticals have increased by +0.1%.

Ibere Pharmaceuticals's Key Ratios

Ibere Pharmaceuticals has a market cap of $175.61 million, indicating a price to book ratio of 1.3034 and a price to sales ratio of 0.

In the last 12-months Ibere Pharmaceuticals’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Ibere Pharmaceuticals's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ibere Pharmaceuticals’s operating margin was 0% while its return on assets stood at -0.9% with a return of equity of 0%.

In Q3, Ibere Pharmaceuticals’s quarterly earnings growth was a negative -54.4% while revenue growth was a positive 0%.

Ibere Pharmaceuticals’s PE and PEG Ratio

Forward PE

0

Trailing PE

17.2542

PEG

Its diluted EPS in the last 12-months stands at $0.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ibere Pharmaceuticals’s profitability.

Ibere Pharmaceuticals stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -167.3002. Its price to sales ratio in the trailing 12-months stood at 0.

Ibere Pharmaceuticals stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$138.96 million

Total Liabilities

$469004.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Ibere Pharmaceuticals ended 2024 with $138.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $138.96 million while shareholder equity stood at $133.01 million.

Ibere Pharmaceuticals ended 2024 with $0 in deferred long-term liabilities, $469004.00 in other current liabilities, 138842391.00 in common stock, $-5834846.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4453.00 and cash and short-term investments were $4453.00. The company’s total short-term debt was $158,866 while long-term debt stood at $0.

Ibere Pharmaceuticals’s total current assets stands at $113203.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $158866.00 and inventory worth $0.

In 2024, Ibere Pharmaceuticals's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Ibere Pharmaceuticals paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$10.18

52-Week High

$10.75

52-Week Low

$9.88

Analyst Target Price

$

Ibere Pharmaceuticals stock is currently trading at $10.18 per share. It touched a 52-week high of $10.75 and a 52-week low of $10.75. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $10.14 and 200-day moving average was $9.95 The short ratio stood at 0.14 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 9833.9% are held by institutions.